Wide Ranks

ENTO

Entero Therapeutics Inc.

0.4545

Top Statistics
Market Cap 2 M Forward PE -0.2990 Revenue Growth 0.00 %
Current Ratio 5.49 Trailing PE 0.0321 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.19 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 662479 Total Cash Per Share 0.1390 Total Debt 356030
Total Debt To Equity 0.5030 Current Ratio 5.49 Book Value Per Share 2.31
All Measures
Short Ratio 12.00 % Message Board Id finmb_261738327 Shares Short Prior Month 88686
Return On Equity -0.2639 City Boca Raton Uuid 936bac12-fa04-3d62-b4e0-90c9edaf8870
Previous Close 0.4652 First Trade Date Epoch Utc 1 B Book Value 2.31
Beta 1.22 Total Debt 356030 Volume 20091
Price To Book 0.1969 Last Split Date 1 B Fifty Two Week Low 0.1850
Total Cash Per Share 0.1390 Shares Short Previous Month Date 1 B Target Median Price 36.00
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 36.00
Net Income To Common -9690728 Ask 0.5167 Short Percent Of Float 0.0198
Implied Shares Outstanding 4 M Last Fiscal Year End 1 B Trailing Peg Ratio None
Average Daily Volume10 Day 117710 Average Volume10days 117710 Total Cash 662479
Next Fiscal Year End 1 B Held Percent Insiders 0.0376 Trailing PE 0.0321
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 0.4652
Target Low Price 36.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.5115
Open 0.4507 Free Cashflow -77052864 State FL
Dividend Yield 0.00 % Return On Assets -0.2766 Time Zone Short Name EST
Trailing Eps 14.17 Day Low 0.4124 Address1 777 Yamato Road
Shares Outstanding 4 M Price Hint 4 Target High Price 36.00
Website https://www.enterothera.com 52 Week Change -0.9173 Average Volume 394109
Forward Eps -1.52 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 4.30 % Last Split Factor 1:20 Regular Market Day High 0.4770
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 0.5030
Fifty Two Week High 14.51 Day High 0.4770 Shares Short 94024
Regular Market Open 0.4507 Industry Key biotechnology Bid 0.4531
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0198
Operating Cashflow -13968406 Currency USD Time Zone Full Name America/New_York
Market Cap 2 M Is_nasdaq_100 False Zip 33431
Quote Type EQUITY Industry Biotechnology Long Name Entero Therapeutics, Inc.
Regular Market Day Low 0.4124 Held Percent Institutions 0.0313 Current Price 0.4545
Address2 Suite 502 Enterprise To Ebitda -3.19 Financial Currency USD
Current Ratio 5.49 Industry Disp Biotechnology Number Of Analyst Opinions 1
Country United States Float Shares 4 M Two Hundred Day Average 2.06
Enterprise Value 63 M Forward PE -0.2990 Regular Market Volume 20091
Ebitda -19989668 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases.

The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.

It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.

The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024.

Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.